Why McKesson (MCK) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • 13 hours ago

McKesson (MCK) Earnings Expected to Grow: Should You Buy?

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 28, 2026

Here's Why McKesson (MCK) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Oct 27, 2026

McKesson (MCK) Stock Dips While Market Gains: Key Facts

In the most recent trading session, McKesson (MCK) closed at $967.02, indicating a -2.6% shift from the previous trading day.

Zacks Investment Research • Oct 27, 2026

McKesson: AI And FDA Overhaul Likely To Overtake Regulatory Drag In 2027

McKesson Corp. stands out as an asset-heavy distributor poised to benefit from AI-driven prescription automation and expedited FDA rare-disease drug approvals. MCK's specialty and oncology segment, with 41% YoY profit growth and superior margins, insulates it from AI disintermediation risks affecting vertically integrated telehealth peers. Despite materially faster EPS growth (24% forward GAAP), MCK trades at only a modest premium (forward P/E 25.75x), with a PEG ratio of 0.55x, suggesting undervaluation.

Seeking Alpha • Oct 22, 2026

McKesson Corporation Declares Quarterly Dividend

IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 94 cents per share of common stock. The dividend will be payable on January 4, 2027, to shareholders of record on December 1, 2026. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufact.

Business Wire • Oct 21, 2026

Is Trending Stock McKesson Corporation (MCK) a Buy Now?

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • Oct 21, 2026

McKesson (MCK) Outperforms Broader Market: What You Need to Know

In the latest trading session, McKesson (MCK) closed at $1, marking a +1.95% move from the previous day.

Zacks Investment Research • Oct 20, 2026

Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.

Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.

Market Watch • Oct 19, 2026

Jim Cramer: This Health Care Stock Is A ‘Winner', X-Energy Is ‘Losing Too Much Money'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said McKesson Corporation (NYSE:MCK) is a “winner” and it will go much higher. “It is exactly what you buy in this environment," he added.

Benzinga • Oct 15, 2026